🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

T1: It was surprising to learn just how many different types of immunotherapies there are - that it isn't just one thing but a collection of tools based on targeted strategies. #gyncsm

T2: Currently, both #cervicalcancer and endometrial cancer have tumor type-specific FDA approvals. Each of these indications requires some molecular testing on the tumor to help determine which regimen would be best. (1/2) #gyncsm

This is a great review! Here's another excellent one specific to #ovariancancer #gyncsm ascopubs.org/doi/full/10.12…

T2: There are also broader approvals that are based on a molecular test result, such as mismatch repair deficiency or high tumor mutational burden, that have immunotherapy approvals for any type of #Cancer. (2/2) #gyncsm

T2: the Society for Gynecologic Oncology SGO is hosting their meeting March 16-18. So stay tuned over the next few days to #SGOMtg for updates on immunotherapy and all things gyn cancer related. We'll do a #gyncsm research update chat this summer.

GYN Cancer | #GYNCSM T3: There is a need to improve access to molecular tests, especially in developing countries. This limits the decision to use immunotherapy. #gyncsm

T3: The individual and doctor would discuss the pros/cons of both the immunotherapy and the other treatment choices. Certain medical conditions, like some autoimmune diseases, may make it less safe to use immunotherapy. #gyncsm

T3: Even if no immunotherapy is approved, remember that many other immunotherapies are being tested in #clinicaltrials for many different types of #Cancer ! #gyncsm

T4 CancerDotNet has a list of overall side effects for immunotherapies cancer.net/navigating-can… #gyncsm

T4: In general, I've found that many people feel well while receiving treatment with an ICI, and may end up staying on this treatment for several yrs if it works well. Side effects are different than chemo #gyncsm

T4: Like any cancer treatment, side effects vary widely between individuals. It important to stay in communication with your healthcare team about side effects and there are many options to try to mitigate various side effects. #gyncsm

T4: Side effects are different from traditional chemo, and are often due to inflammation by the immune system; so-called “-itis” es. Ex colitis (inflammation of the colon), thyroiditis (of the thyroid), hepatitis (liver), etc. #gyncsm

T5/6 One good resource is Society for Immunotherapy of Cancer (Society for Immunotherapy of Cancer ) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer jitc.bmj.com/content/11/6/e… #gyncsm

T5/6: I am really excited about the future of immunotherapy in #gynonc ! The way we learn more is through #clinicalresearch and #clinicaltrials. Lots of exciting new types of immunotherapies are coming down the pipeline #gyncsm

TIL: Dr. Odunsi of UChicagoCancerCenter is talking about ovarian cancer immunotherapy tomorrow! He is one of the world's leading experts, excited to hear what he will discuss #gyncsm

#SGOMtg important pilot work in #uterinecarcinosarcoma to better understand response to immunotherapy Ayesha Kar, MD Sanaa Nakad Borrego dr gini Fleming John Moroney Katie Kurnit great project and mentoring! UChicago Obstetrics and Gynecology Department UChicagoCancerCenter

Special thanks to Dr Jenny Bennett, MD for her Gyn path and molecular expertise- a coauthor on the abstract inadvertently left off the poster but who did an incredible amount of work!!

The call for proposals is just days away! Mucinous Ovarian Cancer Coalition/MOCC invites researchers to submit abstracts for requests of up to $50,000. Find the full guidelines here: hope4moc.org/researching/ Michael Frumovitz Katie Kurnit Jenny Mueller MD SGO

Join us next Sunday night for a discussion of low grade serous #ovariancancer with OncLive.com if you’re in Chicago for #asco24! Link: event.onclive.com/event/9318b8ba…

🗓MONDAY, AUGUST 19 ⏰5:00PM (GMT+3)/ 9:00AM (EST) An introduction to the field of gynecologic oncology with Dr. Katie Kurnit focusing on the role of specialists in diagnosing in managing cancers of the female reproductive system.